Drug products: Ebetrex, Emthexate, Injexate, Maxtrex, Metex, Methotrexat, Methotrexat "Lederle", Methotrexat Pfizer, Methotrexate Ebewe, Methotrexate Orion, Methotrexate Orion Pharma, Methotrexate Paranova, Methotrexate Pfizer, Methotrexate Sandoz, Methotrexate Teva, Methotrexat-Teva onco, Metoject, Metojectpen, Metotab, Nordimet
ATC code: L01BA01, L04AX03
Substances: methotrexate, methotrexate disodium
Although methotrexate can have good effect in men and women, the effect has been shown to be better in men with rheumatoid arthritis.
Studies suggest a better response to methotrexate in men with rheumatoid arthritis than women.
Methotrexate can cause teratogenic effects when administrated to a pregnant woman. For Swedish users, more information can be found in
Janusmed Drugs and Birth Defects
One study of methotrexate pharmacokinetics in children showed no differences between boys and girls . No other studies with significant sex differences in pharmacokinetics have been found. No studies with a clinically relevant sex analysis regarding the dosing of methotrexate have been found.
A randomized controlled trial in patients with new-onset rheumatoid arthritis (RA) treated with methotrexate (87 men, 318 women) showed that women were less likely to respond to methotrexate (odds ratio 0.50), measured both with ACR and EULAR criteria . Similar results have been shown in another study in patients with either new-onset RA (47 men, 139 women)  or established RA (122 men, 289 women) .
Treatment response to methotrexate has been analyzed in patients with idiopathic inflammatory myopathy in a retrospective cohort study (40 men, 73 women). Complete response to methotrexate was found in 8 of 24 men but only in 1 of 31 women .
A Swedish observational study (252 men, 446 women) showed that fewer women than men with RA receiving anti-rheumatic agents (mainly sulfasalazine or methotrexate) were in remission at follow-up at 2 and 5 years. Women had a higher doctor-assessed disease activity at baseline. After treatment, disease activity decreased less in women than in men .
The risk of cancer associated with methotrexate compared with other biologic disease-modifying anti-rheumatic drugs have been examined in patients with RA in an observational study (1591 men, 5215 women). Men had a higher risk of any cancer (hazard ratio for female 0.50) .
Sex differences in the incidence of liver test abnormalities in patients with RA treated with low-dose methotrexate (71 men, 92 women) have been found. Toxic elevations in transaminases were seen more frequently in women . Another study including patients with RA or psoriasis shows similar results (374 men, 435 women). Women were more likely to have liver enzyme elevation from long-term treatment with methotrexate (hazard ratio 1.43) . The incidence of liver toxicity compared to clinical response of methotrexate in juvenile idiopathic arthritis has been analyzed in a retrospective cohort study (48 boys, 172 girls). One cohort received initial high-dose of methotrexate (>0.5 mg/kg/week) and one cohort received initial low-dose methotrexate (< 0.5 mg/kg/week). Girls receiving high-dose had a greater risk of liver toxicity at 12 months compared to girls on low-dose (odds ratio 3.7). Boys receiving high-dose had no increased risk of toxicity. However, this finding could be due to the relatively small number of boys in the cohort .
Methotrexate is contraindicated in pregnant women and breastfeeding mothers. Methotrexate can cause fetal harm when administered to a pregnant woman. It is recommended that pregnancy should be avoided if either partner is receiving methotrexate. For male patients, their female partner should avoid pregnancy during therapy and for a minimum of three months after therapy. For female patients, pregnancy should be avoided during and for at least one ovulatory cycle after therapy . Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Sex-specific differences in treatment of severe psoriasis have been analyzed using data from national surveys including 4.1 million men and 4.4 million women. Of patients receiving methotrexate, 79% of the men and 18 % of the women were 50 years old or younger.. For patients older than 50 years, women were more likely than men to receive intensive treatment. For patients younger than 50 years, men were three times more likely than women to receive intensive treatment. This observation might be explained by a reluctance to use potentially teratogenic drugs in women of childbearing potential .
Despite the risk of teratogenic effects of methotrexate, one study found no sex difference in methotrexate use in teenagers with Crohn disease or ulcerative colitis .
Date of litterature search: 2015-07-10
Reviewed by: Mia von Euler, Karin Schenck-Gustafsson
Approved by: Karin Schenck-Gustafsson